Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07787429 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma

Study acronym: Dragonfly
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 16 words
    • Study description expanded, about 7 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Anna Raciborska
5 trials monitored
See all monitored trials
Sarcoma
1,026 trials monitored
See 67 trials at risk
Prospective, open, interventional, randomized, non-commercial trial
Trial Details
NCT Number NCT07787429
Lead Sponsor Anna Raciborska
Collaborators: Maria Sklodowska-Curie National Research Institute of Oncology
Conditions
(from sponsor)		 Osteosarcoma
Related terms Osteosarcoma
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov